In this video, Dr. David Valle, speaks about how genetic variations impact patients' antibodies and immune systems in different ways. "We are beginning to gather the knowledge that is necessary to recognize the key individual differences that determine why patients behave in different ways, even though they have the same diagnostic label," says Valle.
In this video, Dr. David Valle, speaks about how genetic variations impact patients' antibodies and immune systems in different ways. "We are beginning to gather the knowledge that is necessary to recognize the key individual differences that determine why patients behave in different ways, even though they have the same diagnostic label," says Valle.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More